Clinical Trial Update: Metabolic and Renal Effects of Rosiglitazone in Kidney Transplant [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluated the metabolic and renal effects of rosiglitazone in kidney transplant recipients; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• Rosiglitazone (rosiglitazone)

Snippet

Sponsor: Mario Negri Institute for Pharmacological Research | Conditions: Kidney Transplant | Phase 2 | Status: COMPLETED